TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT05357378: Safety and Effectiveness of the HIT Reverse HRS

Sponsor: Hip Innovation Technology · Phase: PHASE2 · Area: IMMUNOLOGY · Target Enrollment: 288 pts

Competing Trials Overlap

6 Active Trials

Excess Burn Exposure

$11,040,000

Rescue Site Savings

+$7,279,500

Unlock Full NCT05357378 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05357378 Rescue Dossier →